摘要
目的探讨孟鲁司特对哮喘患者外周血白细胞介素10(IL-10)、白细胞介素25(IL-25)、嗜酸性粒细胞和免疫球蛋白E(IgE)水平的影响。方法对治疗组45例急性发作期哮喘患者予孟鲁司特钠片10 mg口服,每晚1次,连用3月,分别在治疗前和治疗3月后抽取静脉血检测血浆IL-10I、L-25、嗜酸性粒细胞计数和IgE水平,检测治疗前后肺功能并观察日夜间症状。以同期入选的健康体检者30例作为对照组。结果治疗组患者治疗前血浆IL-25和IgE水平、嗜酸性粒细胞计数明显高于对照组I,L-10水平明显低于对照组(P<0.05或P<0.01);与治疗前比较,治疗3个月后患者IL-25和IgE水平、嗜酸性粒细胞计数明显降低I,L-10水平明显上升(P<0.05),且肺功能和日夜间症状均明显改善(P<0.01)。结论孟鲁司特治疗哮喘的临床疗效确切,能明显改善患者的日夜间症状和肺功能;其作用机制可能是通过下调血浆IL-25水平、上调IL-10水平,从而抑制嗜酸性粒细胞聚集,使B淋巴细胞分泌IgE减少。
Objective To investigate the effect of montelukast on plasma IL-10,IL-25 and IgE levels and eosinophils（EOS） count in the patient with asthma.Methods Forty-five cases of asthma in acute attack period as the treatment group were treated with oral montelukast 10 mg,once every night for 3 months.The plasma IL-10,IL-25 and IgE levels and EOS count before and after 3-month treatment were detected.The lung function was also determined.The daytime and night symptoms were observed.30 cases of healthy check-up in the same period were selected as the control group.Results The levels of plasma IL-25,IgE and EOS count before treatment in the treatment group were significantly higher than those of the control group,while plasma IL-10 level was significantly lower than that of the control group（P 0.05 or P 0.01）.The levels of plasma IL-25,IgE and EOS count after 3-month treatment were significantly decreased,while IL-10 level was significantly increased after treatment（P 0.05）.Also the lung functional parameters,daytime and night symptoms were improved singnificantly（P 0.01）.Conclusion Taking oral montelukast to treat the asthma has the definite curative effect,which can improve the lung function and clinical symptoms.The mechanism of montelukast in the treatment of asthma may inhibit the aggregation EOS and reduce IgE secretion of B lymphocytes by down-regulating the plasma IL-25 level and up-regulating the plasma IL-10 level.
出处
《中国药业》
CAS
2011年第11期16-17,共2页
China Pharmaceuticals
